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used for mortality and ANCOVA was used for LOS with con-
founding factors adjusted in the models. Adjusted factors
included patient demographics, hospital characteristics (bed size,
region, teaching and PCI annual volume), co-morbid conditions
(chronic obstructive pulmonary disease, peripheral vascular
disease, diabetes mellitus, malignancy, acute renal failure) and
severity. RESULTS: Patients treated with nesiritide had signiﬁ-
cantly higher average hospital charges vs. not treated ($48,493
vs. $27,315, t = 22.94, p < 0.001). No better outcomes were
observed in nesiritide treated patients measured by LOS (10.03
vs 6.54, t = 22.71, p < 0.001) and mortality (Chi = 2.94, p =
0.086). The increased LOS (p < 0.001) in nesiritide treated group
were supported by ANCOVA model with control for covariates
including severity, mortality and payor type. Further analysis in
mortality by using conditional logistic regression showed con-
sistent results. CONCLUSIONS: Patients treated with nesiritide
are associated with higher costs, LOS and were not found to
obtain a cost effective therapy during their hospital stay. To
conﬁrm the ﬁnding, further study in inpatient settings and more
efﬁcient methods e.g. propensity score analysis are suggested to
better control for inﬂuencing factors.
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OBJECTIVES: To determine the impact of adherence to statin
therapy on the incidence of cardiovascular events in a Medicaid
managed care population. METHODS: Retrospective database
analysis of Maryland Medicaid medical and pharmacy claims for
the period January 1, 2001–December 31, 2003. Inclusion cri-
teria: Continuously enrolled patients older than 18 years who
had at least one prescription claim for any of the statins. Exclu-
sion criteria (to obtain incident cohort): Patients who had at least
a claim before July 1st, 2002. Non-adherence was deﬁned as a
failure to reﬁll a prescription claim. Logistic regression models
were built to determine the association of drug adherence
adjusted for age, gender, race, comorbidities (based on Charlson
Comorbidity Index) with cardiovascular events. RESULTS: Out
of a total of 1997 patients, most were females (61%), African
Americans (57%), and 60 years old or younger (70%). Based on
univariate analysis, persistent patients had a lower incidence of
cardiovascular events than non-persistent patients (19% vs.
32%), females a lower incidence than males (24% vs. 35%) and
African Americans a lower incidence than Caucasians (24% vs.
34%). In the logistic regression model adjusting for comorbidi-
ties and demographics, drug adherence (OR 0.460, 59% CI
0.357, 0.593), African American race (OR 0.596, 95%CI 0.485,
0.734), and male gender (OR 1.674, 95% CI 1.369, 2.047) were
signiﬁcantly associated with CV events. CONCLUSION: In this
Medicaid population of statin users, the incidence of cardiovas-
cular events is higher in males, Caucasians and in patients who
do not adhere to statin therapy. Risk management programs may
need to focus on drug adherence among statin users, as one of
the major modiﬁable factors to reduce cardiovascular events.
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OBJECTIVES: Achieving combined optimal lipid values (OLVs)
for LDL-C, HDL-C, and triglycerides (TG) is associated with
reduced cardiovascular events; however little is known about the
subsequent loss of OLV. This study evaluated the loss of OLV
and associated cardiovascular events in a managed care (MCO)
population. METHODS: Patients were selected from a 2.1
million record database based on: lipid panel between January
1, 2000 and December 1, 2001, no concomitant lipid therapy,
and continuous eligibility for 24 months. Patients were catego-
rized as 1°/2° prevention, male/female, and diabetes mellitus
(DM). Guidelines deﬁned OLVs: NCEP ATP III (1° and 2° pre-
vention, men), AHA (women), and ADA (DM). Combined OLV
achievement was determined, as were cardiovascular events
based on ICD-9/CPT codes. The association between loss of
combined OLV achievement and cardiovascular events was eval-
uated by multivariate logistic regression and calculated odds
ratios (OR). RESULTS: The study included 44,351 patients: 1°
prevention (23,403); 2° prevention (20,948); males (22,345);
females (22,006); and DM (8,164). Mean age was 64 ± 13 years,
with a follow-up of 30 ± 12 months. Baseline lipids (mg/dL):
total cholesterol 210 ± 40; LDL-C 131 ± 35; HDL-C 48 ± 14;
and, TG 159 ± 77. Baseline combined OLV was achieved in
8–13%, which increased to 17–21% during follow-up. There
were 10,899 cardiovascular events experienced in 6,722 patients.
Loss of combined OLV was associated with an increase in car-
diovascular events in the total population (OR 1.43, 95% CI,
1.30–1.57). Subgroups demonstrated a similar increase in events
(OR: 1.40 to 1.67; 95% CI, 1.28 to 1.88) except 1° prevention
(OR, 1.2; 95% CI, 1.0–1.3). CONCLUSION: Combined OLVs
were achieved by <25% of patients. Loss of combined OLV
achievement was associated with a signiﬁcant 40 to 67%
increase in cardiovascular event risk, excepting 1° prevention
patients. Maintaining combined OLV achievement has the poten-
tial to signiﬁcantly improve outcomes across a wide spectrum of
patients.
PCV11
EVALUATION OF A MAIL-BASED WARFARIN (COUMADIN®)
PATIENT EDUCATION INITIATIVE IN A MANAGED CARE
SETTING
Hoffman L1, Pendergrass A1, Sarawate C2, Bullano M2
1Blue Cross and Blue Shield of Florida, Inc, Jacksonville, FL, USA,
2HealthCore, Inc, Wilmington, DE, USA
OBJECTIVES: Adverse drug events (ADEs) associated with war-
farin therapy result in signiﬁcant morbidity, mortality, and eco-
nomic costs. Previous studies have demonstrated that ADEs are
associated with a Prothrombin Time (PT) or International Nor-
malized Ratio (INR) value outside of the accepted therapeutic
range. The purpose of this study is to evaluate the effectiveness
of a mail-based warfarin education program in improving
member PT/INR values and reducing ADEs and medical and
pharmacy costs in a managed care setting. METHODS: A total
of 1401 members initiated on warfarin therapy were random-
ized to an intervention or control group. The intervention group
received a series of six educational letters, which included infor-
mation about warfarin, the importance of PT/INR testing, signs
and symptoms of supra- and sub-therapeutic PT/INR values, and
a reminder to schedule physician appointments. Members were
followed for a mean of 341.5 days after initiation of warfarin.
